9.04
2.06%
-0.19
アフターアワーズ:
9.04
Amicus Therapeutics Inc (FOLD) 最新ニュース
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Zacks Investment Research
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks Investment Research
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire Inc.
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Zacks Investment Research
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Zacks Investment Research
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
GlobeNewswire Inc.
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
GlobeNewswire Inc.
Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?
Investing.com
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
Zacks Investment Research
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
GlobeNewswire Inc.
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Zacks Investment Research
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Benzinga
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?
Zacks Investment Research
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
GlobeNewswire Inc.
大文字化:
|
ボリューム (24 時間):